Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine
NCT00424671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2007-06-22
Summary
This study will assess the influence of moderate hepatic impairment on the pharmacokinetics of licarbazepine after single oral administration in healthy subjects and in subjects with stable impaired hepatic function.
Conditions
- Healthy
Interventions
- DRUG
-
Licarbazepine
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Investigative site
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-11-30
Countries
- Czechia
Study Locations
More Related Trials
-
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
NCT04819464 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
NCT03040479 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
NCT01012284 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476 ·Status: COMPLETED ·Phase: PHASE1
-
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
NCT01901133 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers
NCT02004587 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
NCT04960124 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
NCT00418626 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
NCT00416702 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
NCT01950481 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001
NCT06619054 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
NCT01465412 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT04482270 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects
NCT03826641 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
NCT04791553 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
NCT02231450 ·Status: COMPLETED ·Phase: PHASE1
-
A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838
NCT01356550 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612 ·Status: COMPLETED ·Phase: PHASE1
-
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
NCT04252417 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
NCT05751759 ·Status: COMPLETED ·Phase: PHASE1
-
PK Study in Subjects With Severe Hepatic Impairment
NCT03664544 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
NCT02170571 ·Status: COMPLETED ·Phase: PHASE1